Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status

April 2, 2024 9:15 AM

Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56% of all users) underscoring the significant potential benefits of technology assistance in an OTC setting(Please see important safety information below)NEW YORK, NY / ACCESSWIRE / April 2, 2024 / Petros Pharmaceuticals, Inc. (Nasdaq:PTPI), a company...

Read more

BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)

April 2, 2024 9:15 AM

Agreement covers Phase 1/2a trial with TNFR2 agonist antibody BI-1910First data from BI-1910 single agent arm expected by YE 2024LUND, SWEDEN / ACCESSWIRE / April 2, 2024 / BioInvent International AB ("BioInvent") (STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces a clinical trial collaboration and supply...

Read more

Edesa Biotech to Participate in Upcoming Investor Conferences

April 2, 2024 9:00 AM

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, announced today that Edesa management plans to participate in the following upcoming investor conferences:Mintz Conference, Toronto, Canada, April 15, 2024LSX World Congress, London, UK, April 29-30, 2024, with showcase presentation at 4:30 pm...

Read more

Repair Biotechnologies Demonstrates Rapid Reversal of Atherosclerosis in Mouse Models

April 2, 2024 9:00 AM

Following favorable FDA feedback for the treatment of liver disease, the company is preparing further pre-IND meetings with the FDA for the treatment of atherosclerosis and familial hypercholesterolemiaSYRACUSE, NY / ACCESSWIRE / April 2, 2024 / Repair Biotechnologies, Inc. (https://www.repairbiotechnologies.com) announced today that its lipid nanoparticle (LNP)/messenger RNA (mRNA) therapy has rapidly reversed the progression of atherosclerosis...

Read more

Genvor to Participate in BioAgTech World Congress in Raleigh, North Carolina

April 2, 2024 8:31 AM

CHAPEL HILL, NC / ACCESSWIRE / April 2, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today announced that management will attend the 5th BioAgTech World Congress taking place April 22-26, 2024 in Raleigh, North Carolina.The BioAgTech World Congress is produced 'by the BioAg industry and for the BioAg industry' with the objective of enabling...

Read more

XiltriX North America Elevates Its Commitment to Security With SOC 2 Type 2 for Its Monitoring-as-a-Service Offering

April 2, 2024 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / April 2, 2024 / XiltriX North America, LLC, a leading provider of real-time environmental monitoring systems for the life science industry, is proud to announce it has received a clean Service Organization Control (SOC) 2 Type 2 attestation report. Developed by the American Institute of Certified Public Accounts (AICPA), SOC 2 is an extensive auditing procedure that ensures that a company is handling customer data...

Read more

Lumira Ventures Announces Investment in Nocion Therapeutics to Revolutionize Chronic Cough Treatment

April 2, 2024 7:00 AM

TORONTO, ON / ACCESSWIRE / April 2, 2024 / Lumira Ventures is delighted to announce its latest investment in Nocion Therapeutics, a clinical-stage biopharmaceutical company developing first and potentially best-in-class, small molecule charged sodium channel blockers (CSCBs), called Nocions. These innovative compounds are designed to selectively silence activated nociceptors for the treatment of serious conditions involving cough, itch, and...

Read more

Selux Diagnostics Announces Additional $48 Million in Funding

April 1, 2024 8:12 AM

This additional funding comes at the heels of Selux announcing their third FDA 510(k) clearance on their direct from Positive Blood Culture Separator, making them the only single-platform technology capable of delivering rapid AST results for both positive blood culture and isolated colonies.BOSTON, MA / ACCESSWIRE / April 1, 2024 / Selux Diagnostics, Inc., a Boston based Biotech startup whose mission is to combat superbug infections and fight...

Read more

Vibrant Wellness Tickborne Testing Granted New York State Approval

March 29, 2024 9:15 AM

A Significant Milestone in Lyme and Tickborne DiagnosticsSANTA CLARA, CA / ACCESSWIRE / March 29, 2024 / Vibrant Wellness, a leader in specialized diagnostics and personalized health tools, announced today that its Tickborne Testing received approval from The Wadsworth Center, part of the New York State Department of Health.This approval enables Vibrant to provide Lyme disease testing in New York, specifically for Borrelia Burgdorferi IgG/IgM in...

Read more

Cambridge-Based Biotech SynDevRx Announces Scientific Publication Describing Optimized Drug Conjugate Targeting Tumors Sensitive to Obesity/Metabolic Hormones

March 28, 2024 10:00 AM

Innovative pro-drug delivers superior efficacy with improved drug-like properties and safety profileCAMBRIDGE, MA / ACCESSWIRE / March 28, 2024 / SynDevRx, Inc., a pioneering clinical-stage biotechnology company based in Cambridge, Massachusetts, has achieved a significant milestone. The company is delighted to announce the publication of a peer-reviewed research paper describing its optimized MetAP2 inhibitor, evexomostat/SDX-7320, targeting...

Read more

Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers

March 28, 2024 8:15 AM

Topline Results For Progression-Free Survival Expected In Q2 2024CARDIFF, UK / ACCESSWIRE / March 28, 2024 / Biodexa Pharmaceuticals (NASDAQ:BDRX) ("Biodexa"), an acquisition-focused biopharmaceutical company, is developing MTX110 for the treatment of Diffuse Midline Glioma (DMG) in pediatric patients and for Recurrent Glioblastoma (rGBM) in adults; two aggressive brain cancers with universally poor prognoses. The company says early trials of...

Read more

Globestar Therapeutics Update on Project Amethyst(TM) and Recent Financials

March 28, 2024 8:15 AM

RICHLAND, WA / ACCESSWIRE / March 28, 2024 / GlobeStar Therapeutics Corporation (OTC PINK:GSTC) (GSTC), is a clinical stage pharmaceutical company focused on advancing new therapies for Multiple Sclerosis (MS) and other neurological diseases, including but not limited to Rheumatoid Arthritis (RA), released on March 11, 2024 its fiscal year first quarter financials for the quarter ended 12/31/2023. The Company reported that $42,800 of cash was...

Read more

Revolutionizing EV Research: Introducing ONI's Next-Generation End-to-End Solution

March 28, 2024 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 29, 2024 / ONI, the company that brought super-resolution microscopes to your lab benchtop, proudly announces the launch of a next-generation, end-to-end solution for studying extracellular vesicles (EVs). ONI now offers a complete solution for extracellular vesicle sample preparation and analysis, the ONI Application Kit™: EV Profiler 2 with the analysis software AutoEV. Together, they are designed to instill...

Read more

Vicore Announces Presentations at the 2024 American Thoracic Society International Conference

March 28, 2024 3:30 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / March 28, 2024 / Vicore Pharma Holding (STO:VICO)Sessions at ATS to include an oral late-breaking presentation of the final results from the Phase 2a AIR trial of buloxibutid (C21) in IPFAdditional presentations include preclinical and translational data reflecting the potency of buloxibutid's upstream mechanism of action as well as the design of the upcoming Phase 2b ASPIRE trialVicore also to be featured in a...

Read more

Hemogenyx Pharmaceuticals PLC Announces Total Voting Rights

March 28, 2024 3:00 AM

LONDON, UK / ACCESSWIRE / March 28, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company") (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the total issued share capital of the Company as at 28 March 2024 consists of 1,341,815,988 ordinary shares of 1 pence each, none of which are held in treasury. Therefore, the total number of voting rights in the...

Read more

Notice to Annual General Meeting in BioInvent International AB

March 27, 2024 10:15 AM

LUND, SWEDEN / ACCESSWIRE / March 27, 2024 / BioInvent International (STO:BINV) The shareholders of BioInvent International AB (publ), Reg. No 556537-7263, are hereby invited to attend the Annual General Meeting to be held at 4.00 p.m., 3 May 2024 at Elite Hotel Ideon on Scheelevägen 27 in Lund, Sweden.The Board of Directors has decided that shareholders shall be able to exercise their voting rights at the Annual General Meeting also by voting...

Read more

Vicore Publishes the Annual Report for 2023

March 27, 2024 3:20 AM

STOCKHOLM, SWEDEN / ACCESSWIRE / March 27, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, March 27, 2024 - Vicore Pharma Holding AB (publ), unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), today announced the publication of the Annual Report for the financial year 2023.The Annual Report for the financial year 2023 is available on the company's website:...

Read more

Biofrontera Inc. Announces 2024 Annual Meeting of Stockholders and Deadlines for Submission of Stockholder Proposals

March 26, 2024 4:30 PM

WOBURN, MA / ACCESSWIRE / March 26, 2024 / Biofrontera, Inc. (NASDAQ:BFRI) (the "Company"), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced that its 2024 Annual Meeting of Stockholders will be held on June 12, 2024 and that the close of business on April 22, 2024 will be the record date for the determination of stockholders entitled to notice of and to vote at the 2024 Annual Meeting....

Read more

InnoSIGN Appoints Eric Lindquist Chief Executive Officer

March 26, 2024 9:00 AM

MASON, OH and EINDHOVEN, THE NETHERLANDS / ACCESSWIRE / March 26, 2024 / InnoSIGN a clinical stage biotechnology company focused on democratizing precision medicine through its proprietary cell signaling pathway technology, today announced the appointment of Eric Lindquist as Chief Executive Officer (CEO). Eric will succeed Paul van de Wiel, PhD, co-founder and previous CEO, who will remain as Chief Operating Officer and Board observer."We are...

Read more

assisTek Unveils Cutting-Edge Technology Platform to Elevate Clinical Trial Data Collection

March 26, 2024 9:00 AM

Transforming Clinical Research: assisTek's Innovative New Platform Raises the Bar for Data Collection and Patient ImpactDOYLESTOWN, PA / ACCESSWIRE / March 26, 2024 / assisTek, a leading innovator in e-clinical solutions for clinical research, proudly unveils its latest breakthrough: an innovative eCOA platform designed to provide a state-of-the-art user experience in order to enhance the ease of clinical trial data collection. Through the...

Read more